X

Drug Profile

Panomifene

Alternative Names: EGIS 5650; GYKl 13504

Latest Information Update: 14 Sep 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IVAX Drug Research Institute
Developer Egis Pharmaceuticals; IVAX Drug Research Institute
Class Small molecules; Stilbenes
Mechanism of Action Estrogen receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Breast cancer

Most Recent Events

26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research
26 Sep 1997 A clinical study has been added to the pharmacokinetics and adverse events sections
27 May 1997 Phase-II clinical trials for Breast cancer in Hungary (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com